27655-40-9

Basic information

• Product Name: 5-Isoquinolinesulfonic acid
• Synonyms: ISOQUINOLINE-5-SULFONIC ACID;ISOQUINOLINE-5-SULFONIC ACID FOR SINTESIS;ISOQUINOLINE-5-SULPHONIC ACID;5-SULFOISOQUINOLINE;5-ISOQUINOLINESULFONIC ACID;5-ISOQUINOLINESULFONIC ACID MONOHYDRATE;5-ISOQUINOLINESULPHONIC ACID;Isoquinoline-5-SulphonicAcid99%
• CAS NO: 27655-40-9
• Molecular Formula: C₉H₇NO₃S
• Molecular Weight: 209.22178
• EINECS: 1308068-626-2
• Product Categories: Quinolines, Isoquinolines & Quinoxalines;Organic acids;Aromatics Compounds;Aromatics;Sulfur & Selenium Compounds;Quinolines, Isoquinolines & Quinoxalines;Building Blocks;Heterocyclic Building Blocks;Isoquinolines
• Mol File: 27655-40-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 300 °C
• Appearance: /Solid
• Density: 1.4048 (rough estimate)
• Refractive Index: 1.5364 (estimate)
• Storage Temp.: -20?C Freezer
• PKA: -0.98±0.40(Predicted)
• CAS DataBase Reference: 5-Isoquinolinesulfonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoquinolinesulfonic acid(27655-40-9)
• EPA Substance Registry System: 5-Isoquinolinesulfonic acid(27655-40-9)

Safety Data

• Hazard Codes: T,C,Xi
• Statements: 49-23-34-24-36/38
• Safety Statements: 53-26-27-36/37/39-45
• RIDADR: UN 2585 8/PG 3
• WGK Germany: 1
• TSCA: Yes
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 27655-40-9(Hazardous Substances Data)

Usage

Chemical Properties

White Crystalline Solid

Uses

5-Isoquinolinesulfonic acid was used in the synthesis of conjugates of oligoarginine peptides.

InChI:InChI=1/C9H7NO3S/c11-14(12,13)9-3-1-2-7-6-10-5-4-8(7)9/h1-6H,(H,11,12,13)/p-1

Upstream product

• 7664-93-9 sulfuric acid 
• 7732-18-5 water 
• 5984-79-2 isoquinoline; hydrogen sulfate 
• 105627-79-0 isoquinoline-5-sulfonyl chloride hydrochloride 
• 119-65-3 isoquinoline 

Downstream Products

• 105627-79-0 isoquinoline-5-sulfonyl chloride hydrochloride 
• 2439-04-5 5-hydroxyisoquinoline 
• 84468-24-6 (5-isoquinolinylsulfonyl)piperazine 
• 906820-08-4 4-fluoroisoquinoline-5-sulfonyl chloride hydrochloride 
• 105628-07-7 fasudil hydrochloride 
• 936233-08-8 5-{[(2R)-2-methylpiperazin-4-ium-1-yl]sulfonyl}isoquinolin-2-ium dichloride 
• 936233-08-8 5-{[(2S)-2-methylpiperazin-4-ium-1-yl]sulfonyl}isoquinolin-2-ium dichloride 
• 102877-50-9 1,2,3,4-tetrahydro-5-hydroxy-isoquinoline 
• 84468-17-7 N-(2-aminomethyl)-5-isoquinolinesulfonamide 
• 103745-39-7 fasudil 
• 1415682-32-4 C₂₀H₂₁N₃O₂S 
• 109547-31-1 isoquinoline-5-sulfonamide 
• 116970-61-7 N-<2-<(p-nitrobenzyl)amino>ethyl>-5-isoquinolinesulfonamide dihydrochloride 
• 116970-82-2 Isoquinoline-5-sulfonic acid benzyl-(2-benzylamino-ethyl)-amide; hydrochloride 

Relevant articles and documents

Preparation method of tetrahydroisoquinoline derivative

The invention discloses a preparation method of a tetrahydroisoquinoline derivative which is N-Fmoc-1,2,3,4-tetrahydroisoquinoline-5-alcohol. The preparation method comprises the following steps: taking isoquinoline as a starting raw material, loading sulfonic acid groups, hydrolyzing, hydrogenating and carrying out Fmoc protection to obtain a target product. The compound is used as an important medical intermediate.

Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor

VEGFR, ERK and Abl had been respectively identified as good drug targets, and their crosstalk also had been well elaborated. Multitarget drugs were more advantageous for cancer treatment, however, no inhibitors simultaneously acting on the three proteins were developed due to their structural diversities. Herein, N-(4-((2-(2-(naphthaen-1-yl)acetamido)ethyl)carbamoyl)piperidin-4-yl)-6- (trifluoromethyl)nicotinamide (NEPT, 6a) was discovered as an active scaffold against VEGFR-2, ERK-2 and Abl-1 kinases through the combination of support vector machine, similarity searching and molecular docking. NEPT and its derivatives were synthesized by convenient routine, their in vitro anti-proliferative abilities against human liver cancer cell line HepG2 were preliminarily evaluated. A representative compound 6b showed an IC50 value of 11.3 μM and induced significant HepG2 cells apoptosis. Besides, these compounds displayed better anti-proliferative abilities against K562 cells (a cell line with typical hyperactivity of the above multikinases), for example compound 6b exhibited an IC50 value of 4.5 μM. Based on hepatotoxicity case reports of Abl inhibitors, cytotoxicity of synthetic compounds against normal liver cell lines (QSG7701 and HL7702) was studied, 6b had a similar toxic effect with positive control imatinib, and most compounds showed less than 35% inhibition activities at 100 μM. Molecular docking study disclosed interactions of 6b with VEGFR-2, ERK-2 and Abl-1 kinases, respectively. Our data suggested the biological activities of 6b may derived from collaborative effects of VEGFR-2, ERK-2 and Abl-1 inhibition.

SYNTHESIS OF POTENTIAL &β-BLOCKERS DERIVED FROM 5-HYDROXYISOQUINOLINE

The synthesis of N-substituted amides 5-hydroxyisoquinaldate is described.Keywords: 5-hydroxyisoquinoline derivatives, synthesis, elemental and spectral analysis.